BLTE (Belite Bio, Inc American Depositary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by BLTE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | Hendrik Peter Scholl | Chief Medical Officer | Sell | — | — |
| 2026-06-17 | Hendrik Peter Scholl | Chief Medical Officer | Sell | — | — |
| 2026-05-08 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-05-07 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-05-06 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-05-05 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-05-04 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-05-01 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-29 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-28 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-27 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-24 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-23 | Yu-Hsin Lin | Chief Executive Officer | J | — | — |
| 2026-04-23 | Hendrik Peter Scholl | Chief Medical Officer | J | — | — |
| 2026-04-23 | Hao-Yuan Chuang | Chief Financial Officer | J | — | — |
| 2026-04-23 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-22 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-21 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-20 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-20 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-16 | NATHAN L. MATA | Chief Scientific Officer | Sell | — | — |
| 2026-04-13 | Wan-Shan Chen | Director | Sell | — | — |
| 2026-04-13 | Hao-Yuan Chuang | Chief Financial Officer | Sell | — | — |
| 2026-04-13 | Yu-Hsin Lin | Chief Executive Officer | Sell | — | — |
| 2026-04-02 | NATHAN L. MATA | Chief Scientific Officer | A | — | — |
| 2026-04-02 | Wan-Shan Chen | Director | A | — | — |
| 2026-04-02 | Hao-Yuan Chuang | Chief Financial Officer | A | — | — |
| 2026-04-02 | Yu-Hsin Lin | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Financial Officer | 205,264 | — |
| — | Chief Executive Officer | 182,949 | — |
| — | Chief Medical Officer | 16,295 | — |
| — | Director | 9,096 | — |
| — | Chief Scientific Officer | 12 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BLTE quote page; the site-wide leaderboard is on the insider transactions hub.